Norikazu Masuda

29.7k total citations · 10 hit papers
389 papers, 14.0k citations indexed

About

Norikazu Masuda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Norikazu Masuda has authored 389 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 316 papers in Oncology, 162 papers in Pulmonary and Respiratory Medicine and 145 papers in Cancer Research. Recurrent topics in Norikazu Masuda's work include HER2/EGFR in Cancer Research (149 papers), Cancer Treatment and Pharmacology (138 papers) and Breast Cancer Treatment Studies (130 papers). Norikazu Masuda is often cited by papers focused on HER2/EGFR in Cancer Research (149 papers), Cancer Treatment and Pharmacology (138 papers) and Breast Cancer Treatment Studies (130 papers). Norikazu Masuda collaborates with scholars based in Japan, United States and South Korea. Norikazu Masuda's co-authors include Seock‐Ah Im, Hiroji Iwata, Pierfranco Conté, Binghe Xu, Mark E. Robson, Suzette Delaloge, Anne Armstrong, Elżbieta Senkus, Nadine Tung and Susan M. Domchek and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Norikazu Masuda

364 papers receiving 13.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Seock‐Ah Im, Norikazu Masuda et al. New England Journal of Medicine profile →
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

2016 1.2k citations Seock‐Ah Im, Norikazu Masuda et al. profile →
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

2018 777 citations Seock‐Ah Im, Norikazu Masuda et al. New England Journal of Medicine profile →
Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria

2015 603 citations Norikazu Masuda et al. profile →
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

2022 594 citations Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations George W. Sledge, Masakazu Toi et al. profile →
Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples

1999 534 citations Norikazu Masuda et al. profile →
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

2019 497 citations Pierfranco Conté, Seock‐Ah Im et al. profile →
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

2022 114 citations Hope S. Rugo, Seock‐Ah Im et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Norikazu Masuda Japan	45	9.9k	7.0k	4.4k	3.0k	1.7k	389	14.0k
Joohyuk Sohn South Korea	44	7.9k 0.8×	5.6k 0.8×	3.3k 0.7×	1.8k 0.6×	811 0.5×	303	10.9k
Joyce O’Shaughnessy United States	53	10.3k 1.0×	3.9k 0.6×	4.4k 1.0×	3.0k 1.0×	1.4k 0.8×	347	14.0k
Luc Dirix Belgium	65	9.4k 0.9×	3.4k 0.5×	4.6k 1.0×	4.4k 1.5×	1.2k 0.7×	311	14.6k
Sabino De Placido Italy	64	7.8k 0.8×	4.5k 0.6×	3.7k 0.8×	4.4k 1.5×	1.2k 0.7×	381	14.0k
Suzanne Kamel‐Reid Canada	55	4.3k 0.4×	3.6k 0.5×	3.0k 0.7×	4.4k 1.5×	1.2k 0.7×	285	12.1k
Emilio Bajetta Italy	55	10.4k 1.0×	5.8k 0.8×	3.7k 0.8×	3.9k 1.3×	1.6k 0.9×	325	16.6k
Antonio Llombart‐Cussac Spain	43	6.8k 0.7×	3.9k 0.6×	3.5k 0.8×	1.4k 0.5×	1.6k 0.9×	317	9.4k
Vivek Subbiah United States	54	6.0k 0.6×	4.6k 0.7×	3.1k 0.7×	3.7k 1.3×	706 0.4×	599	12.2k
Keyue Ding Canada	45	8.1k 0.8×	8.4k 1.2×	2.6k 0.6×	3.4k 1.1×	641 0.4×	218	14.5k
Neal I. Lindeman United States	49	11.6k 1.2×	13.2k 1.9×	5.8k 1.3×	8.1k 2.7×	1.1k 0.6×	172	22.4k

Countries citing papers authored by Norikazu Masuda

Since Specialization

Citations

This map shows the geographic impact of Norikazu Masuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norikazu Masuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norikazu Masuda more than expected).

Fields of papers citing papers by Norikazu Masuda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norikazu Masuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norikazu Masuda. The network helps show where Norikazu Masuda may publish in the future.

Co-authorship network of co-authors of Norikazu Masuda

This figure shows the co-authorship network connecting the top 25 collaborators of Norikazu Masuda. A scholar is included among the top collaborators of Norikazu Masuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norikazu Masuda. Norikazu Masuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yoshinami, Tetsuhiro, Shigenori E. Nagai, Masaya Hattori, et al.. (2024). Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast Cancer. 31(4). 621–632. 2 indexed citations

Takano, Toshimi, Norikazu Masuda, Mitsuya Ito, et al.. (2024). Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast Cancer Research and Treatment. 207(1). 33–48. 2 indexed citations

Niikura, Naoki, Yuichiro Kikawa, Mari S. Oba, et al.. (2023). Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast Cancer Research and Treatment. 199(2). 253–263. 2 indexed citations

Cescon, David W., Peter Schmid, Hope S. Rugo, et al.. (2023). Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. JNCI Journal of the National Cancer Institute. 116(5). 717–727. 7 indexed citations

Takahashi, Masato, Tomofumi Osako, Hiroyuki Yasojima, et al.. (2023). Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole. Breast Cancer. 31(1). 53–62. 2 indexed citations

Cortés, Javier, Hope S. Rugo, David W. Cescon, et al.. (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 387(3). 217–226. 594 indexed citations breakdown →

Neven, Patrick, Stephen Johnston, Masakazu Toi, et al.. (2021). MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer. Clinical Cancer Research. 27(21). 5801–5809. 7 indexed citations

Yamashiro, Hiroyasu, Hiroji Iwata, Norikazu Masuda, et al.. (2020). Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. Breast Cancer. 27(4). 631–641. 5 indexed citations

Yamashita, Toshinari, Norikazu Masuda, Shigehira Saji, et al.. (2020). Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 21(1). 391–391. 10 indexed citations

10.

Masuda, Norikazu, Hirofumi Mukai, Kenichi Inoue, et al.. (2019). Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer. 26(5). 637–650. 10 indexed citations

11.

Sugie, Tomoharu, Eiji Suzuki, Akira Yamauchi, et al.. (2018). Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer. The Breast. 38. 114–119. 9 indexed citations

12.

Takada, Masahiro, Masahiro Sugimoto, Norikazu Masuda, et al.. (2018). Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Breast Cancer Research and Treatment. 172(3). 611–618. 18 indexed citations

13.

Watanabe, Junichiro, Yoshinori Ito, Toshiaki Saeki, et al.. (2017). Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. In Vivo. 31(3). 493–500. 18 indexed citations

14.

Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology. 35(25). 2875–2884. 1103 indexed citations breakdown →

15.

Yamamura, Jun, Norikazu Masuda, Daigo Yamamoto, et al.. (2017). Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015. Chemotherapy. 62(5). 307–313. 3 indexed citations

16.

Iwata, Hiroji, Hirofumi Fujii, Norikazu Masuda, et al.. (2013). Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study. Breast Cancer. 22(2). 192–200. 7 indexed citations

17.

Cortés, Javier, Sandra M. Swain, Iveta Kudaba, et al.. (2013). Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel. Anti-Cancer Drugs. 24(10). 1084–1092. 19 indexed citations

18.

Aogi, Kenjiro, Toshiaki Saeki, Seigo Nakamura, et al.. (2012). A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). International Journal of Clinical Oncology. 18(4). 598–606. 5 indexed citations

19.

Miyoshi, Yasuo, Masafumi Kurosumi, Junichi Kurebayashi, et al.. (2009). Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer. 17(2). 103–109. 13 indexed citations

20.

Miyoshi, Yasuo, Masafumi Kurosumi, Junichi Kurebayashi, et al.. (2007). Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers. Journal of Cancer Research and Clinical Oncology. 134(5). 561–567. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact